GlobeNewswire·Jun 25, 2026, 7:00 AM ET

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

MCRB

Seres Therapeutics (NASDAQ: MCRB) will host a webcast on July 8, 2026, at 8:30 am ET to discuss top-line results from an investigator-sponsored trial (IST) of SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC).
The IST was conducted at Memorial Sloan Kettering Cancer Center by Principal Investigator David Faleck, M.D., under protocol NCT06801067.
The trial evaluated SER-155 in 15 participants with Grade 2-3 irEC who were naive to immunosuppressive therapy to assess if the treatment can achieve clinical response without corticosteroids.
The primary efficacy endpoint is the proportion of participants achieving an immunosuppressive-free clinical response by Day 15, defined as a 1-grade improvement in diarrhea symptoms without toxic immunosuppressive therapy.
Current standard of care for moderate to severe irEC requires halting immune checkpoint inhibitor (ICI) cancer therapy & initiating corticosteroids, which compromises the immune system & creates an unmet need for immunosuppressive-free alternatives.
SER-155 has received Breakthrough Therapy & Fast Track designations & is being advanced for preventing bloodstream infections in allogeneic hematopoietic stem cell transplant patients while pending funding for Phase 2 readiness.
Seres is also advancing IND-enabling studies for SER-603 for inflammatory bowel disease & previously developed VOWST™, which was divested to Nestlé Health Science.
The press release includes forward-looking statements regarding clinical plans, funding needs, profitability, & potential risks related to regulatory approvals & market acceptance.